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Abstract 
Background 
Antimicrobial resistance (AMR) poses a threat to public health. Clinical microbiology 
laboratories typically rely on culturing bacteria for antimicrobial susceptibility testing (AST). 
As the implementation costs and technical barriers fall, whole-genome sequencing (WGS) 
has emerged as a ‘one-stop’ test for epidemiological and predictive AST results. Few 
published comparisons exist for the myriad analytical pipelines used for predicting AMR. To 
address this, we performed an inter-laboratory study providing participants with identical 
short-read WGS data sequenced from clinical isolates, allowing us to assess the 
reproducibility of the bioinformatic prediction of AMR between laboratories and identify 
problem cases and factors that lead to discordant results.  
Methods 
We produced ten WGS datasets of varying quality from cultured carbapenem-resistant 
organisms obtained from clinical samples sequenced on either an Illumina NextSeq or HiSeq 
instrument. Nine laboratories were provided these sequence data without any other contextual 
information. Each laboratory used its own pipeline to determine the species, the presence of 
resistance-associated genes, and to predict susceptibility or resistance to amikacin, 
gentamicin, ciprofloxacin and cefotaxime. 
Results 
Individual laboratories predicted different numbers of AMR-associated genes and different 
gene variants from the same clinical samples. The quality of the sequence data, choice of 
bioinformatic pipeline and interpretation of the results all contributed to discordance between 
laboratories. Although much of the inaccurate gene variant annotation did not affect 
genotypic resistance predictions, we observed low specificity when compared to phenotypic 
AST results but this improved in samples with higher read depths. Had the results been used 
to predict AST and guide treatment a different antibiotic would have been recommended for 
each isolate by at least one laboratory. 
Conclusions 
We found that participating laboratories produced discordant predictions from identical WGS 
data. These deficits, at the final analytical stage of using WGS to predict AMR, suggest 
caution when using this technology in clinical settings. Comprehensive public resistance 
sequence databases and standardisation in the comparisons between genotype and resistance 
phenotypes will be fundamental before AST prediction using WGS can be successfully 
implemented in clinical microbiology laboratories. 
 
Keywords: Antimicrobial resistance, antimicrobial susceptibility testing, whole-genome 
sequencing, bioinformatics, carbapenem resistance. 
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Introduction 
Antimicrobial resistance (AMR) is a major, global, public health threat with projections of up 
to 10 million deaths per annum by 2050 [1]. The World Health Organisation’s 2015 Global 
Action Plan on AMR identified diagnostics as a priority area for combating resistance [2]. 
Whilst most diagnostic AMR testing is phenotypic antimicrobial susceptibility testing (AST) 
based on principles dating back to the early 20th century [3]. Molecular testing has facilitated 
the implementation of PCR assays that target key AMR mutations and genes [4,5]. However 
there remains an unmet need for truly rapid point-of-care AST [6,7]. 
Whole-genome sequencing (WGS) is emerging as a routine clinical test that could be used to 
determine the bacterial species, undertake transmission tracking and identify multiple AMR 
associated mutations and genes in a single assay [8–13]. Whilst the initial clinical roll-out of 
WGS has used bacterial isolates, metagenomics and sequencing direct from clinical samples 
are future possibilities [14–16]. Resolving the challenges of AMR prediction using WGS for 
bacteria will provide key advances for the application of metagenomics as a clinical test.  
Bioinformatics tools and pipelines to predict AMR have generally been developed by 
individual research groups, many with no clinical expertise, and mostly with the same basic 
principle of matching the input DNA sequence to entries in a reference database of known 
AMR-associated gene sequences. The testing of pipelines for AMR prediction is typically 
either performed in house [17–19] or done ad hoc for specific research [20–23]. Often, these 
tools are not developed with clinical application or portability in mind. Currently there are no 
higher-order reference materials (synthetic references that contain exact components of 
interest) that are available to validate these tools. Studies have reported good concordance 
between genotype and phenotype on datasets they have been applied to [9,21,24], but rarely 
address situations where different methods may produce discordant results and how this 
discordance should be resolved.  
Gaining laboratory accreditation is an important, often essential step for tests in clinical 
microbiology, but is less advanced for bioinformatics due to its comparatively recent 
development. Bioinformatic reproducibility studies have been performed for clinically 
relevant bacterial sequence typing methods [25,26]. However, while there have been intra-
laboratory studies comparing methods of AMR prediction, there have been no comparisons of 
multiple methods at the inter-laboratory scale. As there is limited evidence of robust, 
reproducible analyses in bioinformatic prediction of AMR from clinical WGS data, adoption 
of these methods may be hampered in meeting the necessary accreditation. 
This multi-centre study used genomic DNA sequences from clinical carbapenem-resistant 
organisms (CROs), specifically chosen to be of varying quality and complexity, to identify 
the contributors to discordant AMR predictions between laboratories. The observations made 
underpin our recommendations for future method developments.  
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Methods 
Sample collection and whole genome sequencing 
For the purposes of this study, a panel of ten samples (A-1, A-2, B-1, B-2, C-1, C-2, D, E, F 
and G) were generated from seven clinical isolates (A, B, C, D, E, F and G). The bacteria 
were isolated between 2014 and 2017 from stool specimens from patients attending Great 
Ormond Street Hospital (GOSH) UK or University Hospital Galway (UHG), Ireland. They 
represented six clinically-relevant bacterial species, including diverse Enterobacterales and 
also Acinetobacter baumannii, and contained six distinct families of carbapenemase genes 
(Table 1).  
Phenotypic AST was performed at UHG and GOSH using the EUCAST disk diffusion 
method (http://www.eucast.org) and meropenem, ertapenem, cefotaxime, amikacin, 
gentamicin and ciprofloxacin. The isolates were confirmed as carbapenemase producers by 
PCR at a reference laboratory (Public Health England).  
Total genomic DNA was extracted from isolate sweeps on the EZ1 Advanced XL (Qiagen) 
using DNA Blood 350 µl kits with an additional bead beating step. For eight samples the 
NEBNext Ultra II DNA Library Prep Kit (New England Biolabs) and NextSeq (Illumina) 
150bp paired-end sequencing was used. For two samples Nextera DNA Library Prep Kit 
(Illumina) and HiSeq 100bp paired-end sequencing was used (Table 1). The FASTQ files 
were deposited in the European Nucleotide Archive (PRJEB34513). 
Inter-laboratory study plan 
Potential inter-laboratory participants were invited both in person and by email at the meeting 
“Challenges and new concepts in antibiotics research”, March 2018, at Institut Pasteur, 
France. Fifteen laboratories and research groups were also emailed directly to participate in 
the study. Nine laboratories agreed to participate in the study (labelled Lab_1 to Lab_9). 
These were a mixture of research groups, hospital laboratories, public health laboratories and 
clinical diagnostic companies. Each laboratory was not made aware who the other invited 
participants were.   
Participant laboratories were sent ten paired FASTQ files and were blinded to their contents 
(For participating laboratories samples were labelled AMRIL_1 to AMRIL_10). The samples 
included: Two exact duplicates A-1 and A-2 (renamed copies of the same FASTQ files). Two 
duplicates with different sequence coverage B-1 and B-2 (sequenced from the same isolate, 
but with median read depths of 1.4X and 142.9X respectively). Two samples sequenced from 
the same isolate C-1 and C-2 (sequenced in two different laboratories using NextSeq and 
HiSeq respectively). The remaining four samples D, E, F and G represented diverse bacterial 
species and carbapenemases). 
Laboratories were asked to report a species identification for each pair of FASTQ files 
provided as well as the presence of all AMR-associated genes present in that sample. They 
were asked, using the above data, to make a categorical prediction on whether that sample 
would be resistant to ciprofloxacin, gentamicin, amikacin and cefotaxime. Lastly, laboratories 
were asked to provide a detailed description of the analysis pipeline they used. 
Participants returned results via an Excel spreadsheet (Additional file 1). Results were 
collated for all species identification and resistant or susceptible predictions from each 
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laboratory. Collated AMR-associated genes had each name manually checked between each 
laboratory to identify minor differences in nomenclature used. Individual laboratory methods 
are summarised in Table 2. The full methods submitted by each laboratory can be found in 
Additional file 2. 
 
 
Table 1. Inter-laboratory study sample characteristics. 
Study ID Isolate species Sequencing method Carbapenemase gene 
Median depth 
of coverage 
Comment 
A-1 K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 190.2 Exact duplicate of A-2 
A-2 K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 190.2 Exact duplicate of A-1 
B-1 E. cloacae complex NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 1.4 Very low coverage duplicate of B-2 
B-2 E. cloacae complex NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 142.9 High coverage duplicate of B-1 
C-1 K. oxytoca Nextera DNA + HiSeq 100bp PE OXA-48-like 37.4 Same original isolate as C-2 
C-2 K. oxytoca NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 156.4 Same original isolate as C-1 
D K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE NDM 83.5  
E E. coli Nextera DNA + HiSeq 100bp PE IMP 20.6  
F C. freundii NEBNext Ultra II + NextSeq 150bp PE VIM 32.5  
G A. baumannii NEBNext Ultra II + NextSeq 150bp PE OXA-23-like & 
OXA-51-like 
22.2  
 
 
 
Table 2. Summary of bioinformatic tools used for detecting antimicrobial resistance by  
each laboratory. 
Method 
step 
Lab_1a1 Lab_1b1 Lab_2 Lab_3 Lab_4 Lab_5 Lab_6 Lab_7 Lab_8 Lab_9 References 
Read 
assembly 
shovill 
(SPAdes) 
shovill 
(SPAdes) 
SPAdes 
Unicycler 
(SPAdes) 
No 
assembly 
A5-miseq 
Bionumeric
s 
No 
assembly 
Unicycler 
(SPAdes) 
No 
assembly 
[27–29] 
AMR 
identifier 
RGI c-SSTAR ABRicate 
RGI & 
Resfinder 
ARIBA RGI 
Bionumeric
s E. coli 
genotyping 
plugin 
(BLAST) 
SRST2 ABRicate Genefinder 
[17,19,30–
32] 
Reference 
database 
CARD 
Resfinder 
& ARG-
ANNOT 
CARD 
CARD & 
Resfinder 
CARD & 
ARG-
ANNOT 
CARD Resfinder 
ARG-
ANNOT 
Resfinder 
CARD & 
Resfinder 
(manually 
curated) 
[17,31,33] 
Sequence 
identity 
cut-off 
80% 95% 75% 
80% 
(CARD) & 
90% 
(Resfinder) 
90% 80% 90% 90% 75% 90%  
Sequence 
coverage 
cut-off 
0% 0% 0% 
0% 
(CARD) & 
80% 
(Resfinder) 
20% 0% 60% 90% 0% 100%  
1. Lab_1 provided two sets of results with two separate methods and so have been split into 
Lab_1a and Lab_1b. 
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Results 
Bacterial species identification 
Four of the nine participating laboratories identified all species correctly from WGS data 
(Table 3). This included sample B-1 where we did not expect enough information for a 
correct call. Species misidentifications of D and B-2 at the genus level by lab_5 is likely to be 
human reporting error rather as they correctly identified species in B-1 from a very low read 
depth. Lab-6 used the same web-based tool for species identification as lab_5 (Kmerfinder, 
CGE) but one error was noted where raw sequence reads were inputted instead of assembled 
contiguous sequences (Table 3).  
 
 
Table 3. Species identification for each sample by each laboratory. 
Lab ID A-1 A-2 B-1 B-2 C-1 C-2 D E F G 
REF ID KP KP ECl ECl KO KO KP EC CF AB 
Lab_1 KP KP ECl ECl KO KO KP EC CF AB 
Lab_2 KP KP - ECl KO KO KP EC CF AB 
Lab_3 KP KP Shigella 
phage 
SflV 
ECl KO KO KP EC Citrobact
er sp. 
AB 
Lab_4 KP KP ECl ECl KO KO KP EC Citrobact
er sp. 
AB 
Lab_5 KP KP ECl KP KO KO EC EC CF AB 
Lab_6 KP KP ECl ECl - KO Klebsiella 
sp. 
EC CF AB 
Lab_7 KP KP ECl ECl KO KO KP EC CF AB 
Lab_8 KP KP ECl ECl KO KO KP EC CF AB 
Lab_9 KP KP ECl ECl KO KO KP EC CF AB 
Missing data represent no results reported. Results highlighted in bold represent 
discrepencies. KP: Klebsiella pneumoniae, ECl: Enterobacter cloacae, KO: Klebsiella 
oxytoca, EC: Escherichia coli, CF: Citrobacter freundii, AB: Acinetobacter baumannii. 
  
 
Antimicrobial resistance gene identification 
We compared the number of AMR-associated genes reported by each laboratory in each 
sample and found disparities in the total reported (Figure 1). Lab_1 used two different 
methodologies for identifying AMR-associated genes; these are referred to as Lab_1a and 
Lab_1b. The number of AMR-associated genes reported by each laboratory was affected by 
the choice of database used. Lab_1a, Lab_2, Lab_3 and Lab_5 all repeatedly reported the 
highest number of genes in each sample and all used the Comprehensive Antibiotic 
Resistance Database (CARD) as their reference database. This is due to CARD including 
many sequences from loosely AMR-associated efflux pump genes that are not found in the 
other databases. Lab_4 and lab_9 also used CARD but in combination with other databases 
and selectively reported genes. The number of AMR-associated genes reported be each 
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laboratory was also found to be associated with sequence identity and coverage thresholds 
used to infer a “hit”. Both Lab_2 and Lab_8 used the lowest identity and coverage thresholds 
(75% sequence identity and no coverage threshold) and lab_2 consistently reported the 
highest number of AMR genes in each sample. While lab_8 reported fewer AMR-associated 
genes than lab_2, it did use ResFinder as its reference database rather than CARD, and 
reported the highest number of genes compared with other participants using the same 
database. 
 
All isolates included in this study were carbapenem resistant. The reporting of carbapenemase 
genes from whole-genome sequencing from all laboratories matched the reference PCR result 
in 91% of cases (91/100) (Table 4). Eight of the ten misidentifications occurred in the low 
coverage sample B-1 as would be expected. Differences between reported gene variants of 
blaIMP were seen in sample E. Five laboratories reported blaIMP-1, whereas the other five 
reported blaIMP-34. This discrepancy exactly matched the reference database used with those 
reported blaIMP-1 having used CARD and those who reported blaIMP-34 either having used 
ResFinder or ARG-ANNOT. While the sequences for blaIMP-34 included in each database are 
identical, the choice of blaIMP-1 reference sequence included in both databases only share 85% 
sequence identity. This is due to CARD’s blaIMP-1 reference sequence being isolated from a 
Pseudomonas aeruginosa integron (NCBI accession: AJ223604) and ARG-ANNOT’s 
reference sequence from a Acinetobacter baumannii integron (NCBI accession: HM036079). 
While there is variation at the nucleotide level, both encode the same IMP-1 enzyme. 
 
 
Table 4. Carbapenemase genes identified for each sample by each laboratory and the 
reference laboratory PCR. 
Lab ID A-1 A-2 B-1 B-2 C-1 C-2 D E F G 
REF PCR1 
OXA-48-
like 
OXA-48-
like 
OXA-48-
like 
OXA-48-
like 
OXA-48-
like 
OXA-48-
like 
NDM IMP VIM 
OXA-23-
like + OXA-
51-like 
Lab_1a2 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
Lab_1b2 OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_2 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
Lab_3 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
Lab_4 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 + 
IMP-9 
VIM-4 OXA-23 + 
OXA-66 
Lab_5 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 
Lab_6 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_7 OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_8 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_9 OXA-48 OXA-48 OXA-48-
like 
(uncertain) 
OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
1. Specific carbapenemase PCR results for each sample.  
2. Lab_1 provided different results using two separate methods and so are included as Lab_1a 
and Lab_1b.  
Missing data represent no results reported. 
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We compared all AMR-associated genes identified by each laboratory in each sample. As 
previously noted, the largest discrepancy were the 55 efflux pump gene sequences were 
present only in CARD (Figure S1). To understand the other factors influencing discordant 
reporting we removed these genes that were only present in one database from our 
comparisons (Figure 2). A pairwise comparison between all laboratories found that two 
laboratories only reported the exact same genes within a sample in 2% (18/900) of cases. 
Fourteen of these cases occurred when analysing the two identical samples (A-1 and A-2, 
Figure 2). Although there was little inter-laboratory agreement between genes identified in A-
1 and A-2, there was complete within-laboratory concordance across both samples, exhibiting 
reproducibility within each analysis pipeline. No two laboratories reported the exact same 
combination of gene variants in samples B-2, C-1, D, F and G. There were many clear 
examples where laboratories assigned different gene variants to the same sequence data 
where the reference sequences only differed by a few single nucleotides. This can be seen in 
Figure 2 amongst samples which contained tetracycline resistance genes (tet(A), tet(B) and 
tet(C)), some aminoglycoside modifying enzyme gene variants (aac(3)-IIa and aac(3)-IIc) 
and β-lactamases (blaACT-14 and blaACT-18). We also observed differences between the same 
laboratories analysing samples from the same original isolate. Due to the very low read depth, 
the genes reported in B-1 bore little resemblance to B-2 across all laboratory reported results. 
However even in the samples from the same isolates with sufficient sequencing depth (C-1 
and C-2) we observed differences in the genes identified in four of the nine laboratories. This 
suggests that resequencing, and even small increases in read length, can produce variation in 
results. It is worth noting that all but one of these differences were additional genes identified 
in C-2, which had a higher read depth than B-2 (156 vs 37 median read depth). The additional 
genes in C-2 included ant(3’’)−Ia (lab_2 and lab_8), fosA7 (lab_2 and lab_8) and tet(C) 
(lab_3) but the reported reference coverage of ant(3’’)−Ia and fosA7 was low (17% and 75%, 
respectively) and the sequence similarity between the purported tet(C) sequence and the 
reference was also low (75%). We also found no systematic differences in genes present or 
absent between those laboratories that used tools that required assembly of short reads first 
and those that took unassembled short reads as input (lab_4 and lab_8, ARIBA and SRST2 
respectively). 
 
Phenotypic and genotypic resistance concordance 
Given the differences in the AMR-associated genes identified in the samples by each 
laboratory, we also compared laboratory predictions of antibiotic resistance to phenotypic 
AST results and each other. Two laboratories (lab_2 and lab_4) did not submit any results for 
phenotypic resistance prediction and so were not included in the subsequent analysis. A 
pairwise comparison between genotypic prediction results reported by all laboratories, on all 
antibiotics and samples showed an overall consensus of 79% (864/1092, Figure 3). This 
varied depending on the antibiotic tested with the highest pairwise reporting consensus of 
88% (240/273) between laboratories for ciprofloxacin and the lowest pairwise reporting 
consensus of 72% (197/273) for cefotaxime, which could be understandable given the 
different complexities of the resistance mechanisms involved. When we compared laboratory 
results with the phenotypic AST results, we found an overall sensitivity of 76% and 
specificity of 50%. Broken down by antibiotic, the highest consensus between phenotype and 
genotype was gentamicin (78%, 62/79) and the lowest amikacin (43% 34/79). As expected, 
there was little agreement between predictions within the low read depth sample (B-1) and 
most laboratories predicted a susceptible isolate due to missing data when in fact it was 
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resistant by phenotypic AST. However, when analysing the same isolate at a higher read 
depth (B-2) there was near perfect concordance between laboratory reported genotypes and 
the resistance phenotype, with only two discrepant results reported by lab_3 (ciprofloxacin) 
and lab_7 (amikacin). Lab_3 also reported different results between the two identical samples 
(A-1 and A-2) where A-1 was reported as resistant and A-2 was reported as sensitive. As 
there were no differences in the gene content reported in either sample by this laboratory 
(Figure 2), this is likely to be due to human reporting error. We also identified a single 
discrepancy between amikacin resistance predicted by lab_7 between samples C-1 and C-2 
which both were sequenced from the same isolate. C-1 was reported as sensitive but C-2 was 
reported as resistant and the phenotypic AST result was sensitive, however there was no 
difference in the reported gene content in both samples by lab_7 so it is also another likely 
human reporting error. Excluding the extremely low depth sample, B-1, there were only 2/30 
cases where no laboratory correctly predicted the phenotypic AST result. Both of these results 
were an incorrect resistance prediction for amikacin in C-2 and E but as noted earlier the 
prediction from lab_7 for C-2 was likely human error. 
 
Discussion 
In this study we have shown that laboratories using different bioinformatics pipelines report 
different AMR-associated gene variants when given identical bacterial isolate WGS datasets 
and that this led to differences in reporting of predicted resistance phenotypes. We observed 
good inter-laboratory concordance for genotypic resistance predictions but poor concordance 
with phenotypic AST results. A similar trend has previously been seen in a study of 
Staphylococcus aureus genomes [34]. Concordance in phenotype prediction differed for 
different antibiotic classes. Good concordance was seen comparing WGS with AST results 
for gentamicin, but for amikacin concordance was poor. This may be due to the fact that 
amikacin is not affected by the action of most aminoglycoside modifying enzymes [35]. 
Previous studies predicting antimicrobial susceptibility from WGS data have reported 
sensitivities of 96% and 99% against phenotypic AST as a benchmark [20,21], compared 
with an overall sensitivity of 76% in this inter-laboratory study. It should be noted however 
that some of the data used in this study were purposefully low quality and some of the 
clinical isolates were deliberately chosen to be difficult to characterise as our aim was to 
identify the contributors to discordant results reported between laboratories working on the 
same data in order to provide useful recommendations. 
We found three stages of analysis that contributed to discrepancies in predictions: The quality 
of the sequence data used, the bioinformatic methods (choice of database or software used) 
and the interpretation of those results. Where single gene calling is required (e.g presence of a 
carbapenemase) results are mainly affected by sequence quality. However, once multiple 
genes are involved, all three analytical issues become important. We found the largest 
contributors to discrepant results between the gene variants reported in each sample and the 
phenotypic resistance predictions were the sample read depth and the choice of reference 
resistance gene database. Samples must be sequenced to a sufficient depth as well as 
sufficient coverage for the expected size of the genome, usually inferred by mapping to a 
suitable reference genome, of at least above 90% to ensure even coverage. Based on our own 
experience and these results, we recommend 30X as a lower limit. This also tends to be a 
default setting for many read assembly tools but generally most samples should have a higher 
depth of coverage than this for meaningful prediction. Some participants did flag that they 
would not normally analyse the low coverage samples (<30X) and when if them (B-1, E and 
G) from this analysis sensitivity in comparison to phenotypic AST rises from 76% to 98%. As 
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long as the sequence data produced is of sufficient depth and quality (e.g. current Illumina 
error rates) we have observed the choice of sequencer and DNA library preparation method 
has a small effect on closely related gene variants but little discernible effect on the inference 
of resistance phenotype. 
Some laboratories ran the same set of read data against different reference databases and 
merged the results which led to different gene variants being reported at the same loci. We 
also found reference sequences in different databases for same gene variant can differ by 15% 
nucleotide identity (blaIMP-1 in CARD and ARG-ANNOT). If precise identification of gene 
variants is required, we would strongly recommend avoiding this as it effectively leads to 
‘double-dipping’ using the same reads. Multiple reference databases could be used but after 
screening for reads that have already been assigned a hit against one of the databases. This 
would avoid multiple different genes reported at the same genomic loci. However, it would 
be better to merge the different reference databases and remove the redundant sequences 
before comparisons are made against the test data. Sequence identity, and to lesser extent 
coverage cut-offs, should be kept high when comparing test data to a reference database. 
Based on this study we would recommend using sequence identity cut-off of at least 90%, in 
combination with an up to date reference resistance gene database. Although lowering of 
these thresholds does identify more candidate genes within a sample it did not improve 
concordance with phenotypic AST results in this study.  
There is an overwhelming need for a standardised, centralised database that integrates the 
current knowledge base for linking genotype with resistance phenotype and is not linked to a 
single research group, as previously suggested [10]. There is also a growing need regarding 
computational reproducibility [36,37]. This would deal with many of the issues we have 
raised, such as which sequences to include and what gene nomenclature to use. With strict 
version control, such a resource would allow greater integration of results and be an 
invaluable tool for larger epidemiological studies. Currently, databases are being built for 
organisms such as for Mycobacterium tuberculosis, though this is a less challenging organism 
for genotype-phenotype predictions due to it being highly clonal and lacking an accessory 
genome [38,39]. However, for all other clinically relevant organisms, many of which acquire 
resistance genes through horizontal gene transfer, there is no such resource.  
Laboratories at the moment do not have the tools or knowledge to make good phenotypic 
resistance calls from genotypic data and this is evident from the fact that two laboratories in 
this study did not report any phenotypic resistance predictions as they felt they could find no 
valid method for doing so. At this point in time many research laboratories use these methods 
to track specific resistance genes or one specific resistance mechanism rather than building 
tools for the broad detection of AMR in bacteria. We found in this study that there was 
particularly low concordance between laboratories reporting sensitive isolates compared with 
phenotypic AST. The problem with the inference of phenotype from genotype is that the 
information is either not known at all or is expert knowledge restricted to single laboratories 
working on specific bacteria. In addition to this, although the identification of the presence of 
genes is performed in a systematic way, the prediction of resistance is still performed in an ad 
hoc manner by scientists and therefore subject to user error given the same set of genes. Once 
again M. tuberculosis is providing the first example of the need for a defined decision tree 
when working from the presence of genes to the prediction of phenotypic drug resistance 
[40]. Interpretation and reporting of this genotypic data will need to be subjected to the same 
level of scrutiny as current tests if it is to form part of an accredited laboratory service within 
the healthcare service.  
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A limitation of this study is that we focused on the use of short read sequence data which 
produces sequences far shorter than the length of genes being identified, however we feel this 
is more reflective of the WGS data that is more routinely generated in clinical laboratories at 
this point in time. If these short reads need to be assembled into longer contiguous sequences 
and we found the use of an actively developed short read assembler to be essential for this. 
Web-hosted tools that provide a “black box” solution to assembly and identifying resistance 
from uploaded WGS data should be avoided if possible, because of the lack of 
interpretability. Tools are needed which are open source and can be subjected to thorough 
troubleshooting when erroneous results arise. To this end, permanently employed 
bioinformaticians are required who can provide expert interpretation of the results and update 
approaches as necessary. In this study, tools that either require assembled contigs (ABRicate) 
and those that take unassembled short reads (SRST2 and ARIBA) were capable of producing 
very similar results with no notable effects alone on the predication of phenotypic resistance. 
This hold promise for rapid phenotypic predictions as genome assembly is one of the largest 
bottlenecks in computational analysis time. Other limitations of this study include our focus 
on acquired genes rather than point mutations or many of the other resistance mechanisms 
found in bacteria (e.g. target site modifications and efflux pumps). We also only required 
reporting on categorical resistance predictions. More work needs to be done on the prediction 
of MICs from WGS data before this can be considered for implementation in laboratories. 
This will be aided by more systematic reporting of accompanying MIC data when making 
WGS data available.  
In conclusion, we have identified some of the current the key contributors to discrepancies in 
predicting AMR-associated genes and phenotypes from bacterial isolate WGS data. We have 
provided recommendations for improving the current reporting of results. Even after 
accounting for poor sequence data we found that the current public methods and in particular 
databases, are not adequate tools for the prediction AMR from bacterial WGS data as a 
universal clinical test at this point in time. 
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Figure 1. Number of antimicrobial resistance associated genes identified in each sample 1 by each laboratory. 
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